Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus LIBRITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus LIBRITABS.
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE vs LIBRITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
None Documented
None Documented
Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment.
Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment.
Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%.
Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine